Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, Larson SM. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. An Thorac Surg 2002;73:259-266.
Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, Hoskins WJ, Barakat RR. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid figo grade 3 cancer. Int J Radiat Oncol 2002;54:79-85.
Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, Mychalczak BR, McKee B, Hoskins WJ, Barakat RR. The significance of the amount of myometrial invasion in patients with stage IB endometrial carcinoma. Cancer 2002;95:316-321.
Alektiar KM, McKee A, Venkatraman ES, McKee B, Zelefsky MJ, Mychalczak BR, Hoskins WJ, Barakat RR. Intravaginal high-dose-rate brachytherapy for Stage 1B (FIGO Grade 1, 2) endometrial cancer. Intl J Radiat Oncol 2002;53:707-713.
Allen PJ, Stojadinovic A, Ben-Porat L, Gonen M, Kooby D, Blumgart L, Paty P, Fong Y. The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol 2002; 9:875-80.
Aung L, Gorlick RG, Shi W, Thaler H, Shorter, NA, Healey JH, Huvos AG, Meyers PA. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience. Cancer 2002;95:1728-1734.
Bach AM, Hann LE, Hadar O, Shi W, Yoo HH, Giess CS, Sheinfeld J, Thaler H. Testicular microlithiasis - respond (Letter). Radiology 2002;223:583-584.
Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socio-economic characteristics in the SEER-Medicare database: applications and limitations. Med Care 2002; supp 40; 19-26.
Bach PB, Malak SF, Jurcic J, Gelfand SE, Eagan J, Little C, Sepkowitz KA. The impact of infection by vancomycin resistant enterococcus on survival and resource utilization for patients with leukemia. Infect Control Hosp Epidemiol 2002;23:471-474.
Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis (with editorial). J Amer Med Assoc 2002;287:2106-2113.
Bach PB, Schrag D. Re - Risk charts - putting cancer in context (letter). J Natl Cancer Inst 2002;94:1584-1585.
Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C. Intraperitoneal chemotherapy for ovarian-carcinoma - results of long term follow-up. J Clin Oncol 2002;20:694-698.
Baron RH, Fey JV, Raboy S, Thaler HT, Borgen PI, Temple LK, VanZee KJ. Eighteen sensations after breast cancer surgery: a comparison of sentinel lymph node biopsy and axillary lymph node dissection. Oncol Nurs Forum 2002;29:651-659.
Battleman DS, Callahan M, Thaler H. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of stay in patients with community-acquired pneumonia: a link between quality of care and resource utilization. Arch Intern Med 2002;162:682-688.
Begg CB, Bach PB. Response to "All cause mortality in randomized trials of cancer screening" (letter). J Natl Cancer Inst 2002;94:861-866.
Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity following radical prostatectomy (with editorial). N Engl J Med 2002; 346:1138-1144.
Begg CB, Schrag D. Attribution of deaths following cancer surgery (editorial). J Natl Cancer Inst 2002;94:1044-1045.
Begg CB. A comparison of methods to detect publication bias in meta-analysis (letter). Stat Med 2002;21:1803.
Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance (with editorial). J Natl Cancer Inst 2002;94:1221-1226.
Begg CB. The mammography controversy (with commentaries). The Oncologist 2002;7:174-176.
Berman E, Little C, Teschendorf B, Jones M, Heller G. Financial analysis of patients with newly diagnozed acute myelogenous leukemia on protocol or standard therapy. Cancer 2002;95:1064-1070.
Berwick M, Matullo G, Vineis P. DNA repair as a biomarker. IN Wilson S, Suk, W. Technology-Driven Biomarker Development Application in Environmentally-Associated Diseases. Ch. 7, CRC Press, 2002; pp 83-108.
Berwick M. Patterns of sun exposure that are important in melanoma. In Newton-Bishop J, Dore J. Challenges in Melanoma. Blackwell Scientific Publishers, Oxford University 2002 pp 3-15.
Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TW, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Analysis of clinical stage T2 prostate cancer: Do current subclasssifications represent an improvement? J Clin Oncol 2002;20(8):2025-2030.
Carson SS, Bach PB. The epidemiology and costs of chronic critical illness. Crit Care Clin 2002;18:461+.
Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res 2002;12:381-387.
Cheung NK, Modak S, Vickers AJ. Physical chemical characterization of oral b -glucan that enhances anti-tumor effects of antibodies in mice. Cancer Immunol Immunother 2002;51(10):557-64.
Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H. Peritoneal metastases - detection with spiral CT in patients with ovarian cancer. Radiology 2002;223:495-499.
Coakley FV, Wei DC, Kattan MW, Eberhardt S, Scardino PT, Hricak H. Urinary continence after radical retropubic prostatectomy: relationship to membranous urethral length on preoperative endorectal MR imaging. J Urol 2002; 168 (3): 1032-1035.
Collins JJ, Devine TD, Dick GS, Johnson EA, Kilham HA, Pinkerton CR, Stevens MM, Thaler HT, Portenoy RK. The measurement of symptoms in young children with cancer - the validation of the Memorial symptom assessment scale in children aged 7-12. J Pain Symptom Manage 2002;23:10-16.
Coogan PF, Rosenberg L, Palmer J, Strom BL, Zauber AG, Shapiro S. The relationship of statin use to the risk of breast and prostate cancer. Epidemiology 2002; 13:262-267.
Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, DePalma D, Bajorin DF. Phase 1 trial of intravesical gemcitabine in bacillus calmette-guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2002;3193-3198.
Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs. Retropsective analysis of carboplatin and paclitaxel as initial 2nd line therapy for recurrent epithelial ovarian carcinoma - application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002;20:1238-1247.
Dwyer T, Blizzard L, Ashbolt R, Berwick M, Plumb J. Cutaneous melanin density measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma and squamous cell carcinoma of the skin. Am J Epidemiol 2002;155(7):614-21.
Eastham JA, Carver B, Katz J, Kattan MW. Clinical stage T1C prostate cancer: pathologic outcomes following radical prostatectomy in black and white men. Prostate 2002;50(4):236-40.
Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol 2002;20(2):108-115.
Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Clinical-pattern and pathological stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-1647.
Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18F-FDG PET. Q J Nucl Med 2002;46:122-130.
Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002;9:637-645.
Gasparro F, Berwick M, Mitchnick M, Diffey B, Nash J, Mitchel D, Young A, Knowland J, Seykora J, Brown D. Godar D. Sun protective agents: formulations, effects and side effects. IN Katz Fitzpatrick T, Dermatology in General Medicine, 6th Edition. Medical Publishing Division, McGraw-Hill, New York. 2002, pp. 2752-2763.
Geller AC, Colditz G, Oliveria S, Emmons K, Jorgensen C, Aweh GN, Frazier AL. Use of sunscreen, sunburning rates, and tanning bed use among more than 10,000 US children and adolescents. Pediatrics 2002;109:1009-1014.
Giess CS, Thaler H, Bach AM, Hann LE. Clinical experience with upper extremity venous ultrasound in a high-risk cancer population. J Ultrasound Med 2002;21:1365-1370.
Gollub MJ, Ginsberg MS, Cooper C, Thaler HT. Quality of virtual colonoscopy in patients who have undergone raditiona therapy or surgery - how successful are we? Amer J Roentgenol 2002;178:1109-1116.
Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H. Percentage of free PSA is not an independent predictor of organ confinement or PSA recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002; 167: 1306-1309.
Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT, Kattan MW. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 2002;7(4):141-146.
Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian P, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, deKernion J, Cangiano T, Schröeder FH, Wildhagen MF, Scardino PT, Kattan MW. A validation study of the accuracy of a postoperative nomogram for recurrence following radical prostatectomy for localized prostate cancer. J Clin Oncol 2002; 20(3): 951-956.
Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schroeder FH, Wildhagen MF, van der Kwast TT, Scardino PT, Kattan MW. International validation of a preoperative nomogram for prostate cancer recurrence following radical prostatectomy. J Clin Oncol. 2002; 20(15): 3206-3212.
Gross CP, Soffer B, Bach PB, Rajkumar R, Forman HP. State expenditures for tobacco-control programs and the tobacco settlement. N Engl J Med 2002;347:1080-1086.
Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K. BLM Heterozygosity and the Risk of Colorectal Cancer. Science 2002;297:2013.
Gupta M, Thaler HT, Steinherz L. Presence of prolonged dispersion of QT intervals in late survivors of childhood anthracycline therapy. Pediatr Hematol Oncol 2002;19:533-542.
Harlap S, Olson SH, Barakat RR, Caputo T, Formenti S, Jacobs AJ, Nakraseive C, Xue X. Diagnostic X-rays and risk of epithelial ovarian carcinoma in Jews. Ann Epidemiol 2002;12:426-34.
Harlap S, Olson SH, Curtin JP, Caputo TA, Nakraseive C, Sanchez D, Xue X. Epithelial ovarian carcinoma and fertility of parents. Epidemiology 2002;13:59-65.
Hazan C, Melzer K, Panageas KS, Li E, Kamino H, Kopf A, Cordon-Cardo C, Osman I, Polsky D. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002;95:634-640.
Hedvat CV, Hegde A, Chaganti RSK, Chen B, Qin J, Filippa DA, Nimer SD, Teruya-Feldstein J. Application of tissue microarray technology to the study of non-hodgkin's lymphoma. Hum Pathol 2002;33:968-974.
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
Holen KD, Klimstra DK, Hummer A, Gonen M, Conlon K, Brennan M, Saltz LB. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancrease and related tumors. J Clin Oncol 2002;20:4673-4678.
Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AMC, Dannenberg AJ. Celecoxib a selective cyclooxygenase-2 inhibitor protects against HER-2/neu-induced breast cancer. Cancer Res 2002;62:5405-5407.
Hull GW, Rabbani F, Abbas F, Wheeler TW, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-534.
Hwu W-J, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose finding trial. J Clin Oncol 2002;20:2610-2615.
Irnich D, Behrens N, Gleditsch JM, Stör W, Schrieber MA, Schöps P, Vickers AJ, Beyer A. Immediate effects of dry needling and acupuncture at distant points in chronic neck pain: results of a randomized, double-blind, sham-controlled crossover trial. Pain 2002;99(1-2):83.
Jarnagin WR, Gonen M, DeMatteo RP, Ben-Porat L, Bodniewicz J, Fong Y, Youssef M, Blumgart LH. Improvement in Perioperative Outcome after Hepatic Resection: Analysis of 1803 Consecutive Cases. Ann Surg 2002; 236 (4) 397-407.
Kattan MW, Introduction. Semin Urol Oncol 2002; 20(2):79.
Kattan MW, Leung DHY, Brennan MF. A postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20(3): 791-796.
Kattan MW, Scardino, PT. Prediction of Progression: Nomograms of Clinical Utility. Clin Prostate Cancer 2002; 1(2):90-96.
Kattan MW. Statistical prediction models, artificial neural networks, and the sophism "I am a patient, not a statistic". J Clin Oncol 2002; 20: 885-887.
Kauff ND, Satagopan JM, Scheuer L, Robson ME, Castiel M, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K: Risk-reducing salpingo-oophorectomy in women with BRCA1 and BRCA2 mutations. N Engl J Med 2002;346:1609-1615.
Kemeny N, Tong W, Gonen M, Stockman J, DiLauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase 1 study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol 2002;13:1490-1496.
Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Role of intrathecal methotrexate in the treatment of primary central nervous system lymphoma. J Neurooncol 2002;58:175-178.
Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S, Thaler HT, Romero R. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol 2002;187:1137-1142.
Knight SJ, Nathan DP, Siston AK, Kattan MW, Elstein AS, Collela KM, Wolf MS, Slimack NS, Bennett CL, Golub RM. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer 2002; 1(2):105-114.
Knudsen, BS, Gmyrek, GA, Inra J, Scherr DS, Vaughn ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002 60(6):1113-1119.
Ko LW, Sheu KFR, Thaler HT, Markesbery WR, Blass JP. Selective loss of KGDHC enriched neurons in Alzheimer temporal cortex - does mitochondrial variation contribute to selective vulnerability. J Mol Neuro Sci 2002;17:361-369.
LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL. Comprehensive gene expression analysis of prostate cancer reveals distinct tanscriptional pograms asociated with metastatic dsease. Cancer Res 2002;62: 4499-4506.
Lee LN, Barnswell C, Torre T, Fearn P, Kattan MW, Potters L. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: Multivariate and matched-pair analyses. Int. J. Radiat Oncol Biol. Phys 2002;53(2):282-289.
Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, Venkatraman ES, Alektiar K, Barakat R. Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma. Gynecol Oncol 87: 287-294 (2002).
Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002;63:11-26.
Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial melanocytic tumors. Am J Surg Pathol 2002 16:47-55.
Mahabir S, Coit D, Liebes L, Brady MS, Lewis JJ, Roush G, Nestle M, Fry, D, Berwick M. Randomized, placebo-controlled trial of dietary supplementation of alpha-tocopherol on mutagen sensitivity levels in melanoma patients: a pilot trial. Melanoma Res 2002; 12:83-90.
Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Long term results of combined modality therapy in resectable non-small cell lung cancer. J Clin Oncol 2002;20:1989-1995.
Massion PP, Kuo W-L, Stokoe D, Tressler PA, Olshen AB, Basas J, Chen C, Riedell L, Polikoff D, Jablons DM, Jain AN, Pinkel D, Albertson D, and Gray JW. Genome scanning of non-small cell lung cancer using array comparative genomic hybridization: implications of the PI3-kinase pathway." Cancer Res 62:3636-3640, 2002.
Mazumdar M. The impact of covariate imbalance on the size of the logrank test in randomized clinical trials by Kinukawa N, Nakamura T, Akazawa K, Nose Y (Stat Med 2000;19:1955-1967). (Letter) Stat Med 2002;21:1167.
McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 2002 60(6): 1003-1009.
Modi S, Panageas KS, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman AD. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 2002;20:3665-3673.
Moher D, Soeken K, Sampson M, Ben-Porat L, Berman B. Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine, BMC Pediatrics 2002; 2:3.
Mokhtari M, Bach PB, Tietjen PA, Stover DE. Clinical characteristics of bronchiolitis with organizing pneumonia in cancer. A case series. Respir Med 2002;96:280-286.
Mora J, Gerald WL, Qin J, Cheung NK. Molecular genetics of neuroblastoma and the implications for clinical management: A review of the MSKCC experience. Oncologist 2002;6:263-268.
Mora J, Gerald WL, Qin J, Cheung NKV. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. Cancer 2002;94:2756-2765.
Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59: 913-918.
Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma: a phase II trial of trastuzumab alone and with paclitaxel. Cancer 2002;94:980-986.
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-2381.
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296.
Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;20:302-306.
Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Re-Evaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002;97:660-667.
Nanjangud G, Rao PH, Hegde A, Teruya-Feldstein J, Donnelly G, Qin J, Zelenetz A, Chaganti R. Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphomas. Blood 2002;99:2554-2561.
Nehal KS, Oliveria SA, Marghoob AA, Christos PJ, Dusza S, Tromberg JS, Halpern AC. Beliefs and use of baseline photography in the management of patients with pigmented lesions: A survey of dermatology residency programs in the United States. Melanoma Res 2002;12:161-167.
Neugut AI, Fleischauer AT, Sundararajan V, Mitra N, Heitjan DF, Jacobson JS, Grann VR: "Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study". J Clin Oncol 2002;20:2643-2650.
Nunez RF, Macapinlac H, Yeung HWD, Akhurst T, Finn RD, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. FDG and C-11 PET versus conventional imaging modalities in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002;43:46-55.
Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Pierce HH, Kauff N, Einat P, Jhanwar S, Satagopan J, Oddoux C, Ellis N, Skaliter R, Yahalom J. Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin Cancer Res 2002;8:3813-3819.
Oliveria SA, Altman JF, Christos PJ, Halpern AC. Use of nonphysician health care providers for skin cancer screening in the primary care setting. Prev Med 2002;34:374-379.
Olshen AB, and Jain AN. "Deriving quantitative conclusions from microarray expression data," Bioinformatics, 18:961-970, 2002.
Olson SH, Voigt LF, Begg CB, Weiss NS. Reporting participation in case-control studies [Commentary]. Epidemiology 2002;13:123-6.
Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D. Alteration of p53 pathway in squamous-cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002;20:2980-2987.
Padula GDA, Zelefsky MJ, Venkatraman ES, Fuks Z, Lee HJ, Natle L, Leibel SA. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal-therapy and 3 dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol 2002;52:439-443.
Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock C. Rituximab for aggressive non-hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer 2002;8:371-376.
Panageas KS, Smith A, Gonen M, Chapman PB. An optimal two-stage phase II design utilizing complete and partial response information separately. Control Clin Trials 2002;23:355-366.
Pandit-Taskar N, Gonen M, Kurg L, Larson SM. Prognostic value of 18FDG-PET imaging in small cell lung cancer. Eur J Nucl Med 2003;30:78-84.
Petrowski H, Gonen M, Jarnagin W, Lorenz M, Dematteo R, Heinrich S, Encke A, Blumgart L, Fong Y. 2nd liver resections are safe and effective treatment for recurrent colorectal cancer hepatic metastases from colorectal cancer - a bi-institutional analysis. Ann Surg 2002;235:863-870.
Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C, Osman I. HDM2 protein overexpression correlates with favorable prognosis in primary malignant melanoma, J Natl Cancer Inst 2002;94:1803-1806.
Pothuri B, Chi DS, Reid T, Aghajanian C, Venkatraman E, Alektiar K, Bilsky M, Barakat RR. Craniotomy for central nervous system metastases in epithelial ovarian carcinoma. Gynecol Oncol 2002;87:133-137.
Potosky AL, Warren JL, Riedel E, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 2002;40:562-568.
Potters L, Fearn P, Kattan MW. The role of external radiotherapy in patients treated with permanent prostate brachytherapy. Prostate Cancer and Pros Dis 2002;5:47-53.
Potters L, Fearn P, Kattan MW. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy. 2002;1(1):36-41.
Potters L, Purrazzella R, Brustein S, Fearn, PA, Leibel SA, Kattan MW. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate cancer. Cancer 2002; 95(7): 1451-1456.
Qin J, Berwick M, Ashbolt R, Dwyer T. Quantifying the change of melanoma incidence by Breslow thickness. Biometrics 2002, 58(3):665-70.
Qin J, Leung D, Shao J. Estimation with survey data under non-ignorable nonresponsive or informative sampling. J Amer Stat Assoc 2002;97:193-200.
Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani P, Scardino PT, Kattan MW. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20(2):82-88.
Ross PL, Littenberg B, Fearn P, Scardino PT, Karakiewicz PI, Kattan MW. Paper standard gamble: a paper-based measure of standard gamble utility for current health. Int J Technol Assess Health Care 2002; 18(4): 942-954.
Ruo LY, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, Paty PB, Wong WD, Larson SM, Cohen AM. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002;236:75-81.
Sander C: The journal Bioinformatics, key medium for computational biology. Bioinformatics 2002;18:1:2.
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-3781.
Satagopan JM, Verbel DA, Venkatraman ES, Begg CB. Two-stage designs for gene-disease association studies. Biometrics 2002;58:163-170.
Satagopan JM, Verbel DA, Venkatraman ES, Offit KE, Begg CB. Two-stage designs for gene-disease association. Biometrics 2002;58:163-170.
Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. T cell responses against tyrosinase 368-376 (370D) peptide in HLA A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, GM-CSF, and QS-21 as immunological adjuvants. Clin Cancer Res 2002;8:967-972.
Scher H and Heller G. Picking the winners in a sea of plenty. Clin Cancer Res 2002;8:400-404.
Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-1268.
Schrag D, Bach PB, Dahlman C, Warren JL. Identifying Hospital Characteristics Using SEER-Medicare and Other Claims Data Medical Care 2002; supp 40; 96-103.
Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance for patients with superficial bladder cancer. J Natl Cancer Inst (provisionally accepted).
Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Hospital and surgeon procedure volume as predictors of outcome following rectal-cancer resection. Ann Surg 2002;236:583-592.
Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:3999-4005.
Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenorol J, Wheeler TM, Spencer DM, Slawin, KM. Preoperative Blood RT-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res 2002; 62: 5974-5979.
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim JH, Beck J, Wheeler TM, Slawin KM. Association of pre-operative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins -2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20(3): 833-841.
Shia J, Teruya-Feldstein J, Pan D, Hagde A, Klimstra DS, Chaganti RS, Qin J, Portlock CS, Filippa DA. Primary follicular lymphoma of the gastrointestinal-tract - a clinical and pathological study of 26 cases. Am J Surg 2002;26:216-224.
Shike M, Latkany L, Riedel E, Fleisher M, Schatzkin A, Lanza E, Corle D, Begg CB. Lack of effect of a low-fat, high-fruit, high-vegetable, and high-fiber diet on serum prostate specific antigen of men without prostate cancer. Results from a randomized trial (with editorial). J Clin Oncol 2002;20:3592-3598.
Sklar CA, Mertens AC, Mitby P, Occhiogroso G, Qin J, Heller G, Yasui Y, Robison LL. Risk of disease recurrence and 2nd neoplasms in survivors of childhood cancer treated with growth hormone - a report from the childhood cancer survivor study. J Clin Endocrinol 2002;87:3136-3141.
Smaletz O, Scher H, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer following castration. J Clin Oncol 2002;20(19): 3972-3982.
Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-Allylamino-17-demethogxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-993.
Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, Gonen M, Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 2002;132:353-359.
Sundararajan V, Mitra N, Jacobson J, Grann V, Heitjan DF, Neugut AI "Survival associated with 5-Fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer". Ann Intern Med 136: 349-357, 2002.
Temple L, Baron R, Cody HS, Fey J, Thaler H, Borgen PI, Heerdt AS, Montgomery L, Petrek JA, Van Zee KJ. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Ann Surg Oncol 2002;9:654-662.
Tickoo SK, Hutchinson B, Bacik J, Mazumdar M, Motzer RJ, Bajorin DF, Bosl GJ, Reuter VE. Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminoma with atypical features. Int J Surg Pathol 2002;10:23-32.
Tjuvajev J, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, Finn R, Beattie B, Thaler HT, Larson S, Conti P, Blasberg R. Comparison of Radiolabeled Nucleoside Probes (FIAU, FHBG and FHPG) for PET Imaging of HSV1-tk Gene Expression. J Nucl Med 2002;43:1072-1083.
Turlakow A, Larson S, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelley W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Improved positron emission tomography with 2-fluorodeoxyglucose (FDG-PET) of primary and locally recurrent prostate cancer based on iterative reconstruction and segmented attenuation correction (IRSAC). Q J Nucl Med. 2001 45: 235-44.
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Assessment of molecular markers of clinical sensitivity to single agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-2326
Verbel DA, Heller G, Kelly WK, Scher HI (2001). Quantifying the amount of variation in survival explained by PSA. Clin Cancer Res 2002;8:2576-2579.
Vickers AJ. Botanical medicines for the treatment of cancer: rationale, overview of current data and methodological considerations for Phase I and II trials. Cancer Invest 2002;20(7-8):1069-79.
Vickers AJ. Placebo controls in randomized trials of acupuncture. Eval Health Prof 2002;25(4):421-35.
Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002;20:297-301.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare Data Medical Care 2002; supplement 40: 3-18.
Wilhelm M, Veltman JA, Olshen AB, Jain AX, Moore DH, Kovacs G, Presti JC, and Waldman FM. Array based CGH for the Differential Diagnosis of Renal Cell Cancer. Cancer Res 62:957-960, 2002.
Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Amer 2002;12:1-10.
Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH. Diagnostic and prognostic value of
Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC. Dose volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with 3-dimensional conformal radiation therapy. Int J Radiat Oncol 2002;54:329-339.
Yossepowitch O, Ohori M, Sircari K, Kattan, MW, Scardino PT, Wheeler TM, Reuter VE. Bladder Neck Involvement in Pathological Stage pT4 Radical Prostatectomy Specimens is Not An Independent Prognostic Factor. J Urol. 2002 168(5):2011-2015.
Yossepowitch O, Olvera N, Ben Porat L, Satagopan JM, Huang H, Jhanwar S, Rapaport B, Boyd J, Offit K. BRCA1 and BRCA2 germline mutations in lymphoma patients. Leuk Lymphoma 2002;44:127-131.
Zauber AG, Winawer SJ. Screening colonoscopy in colorectal cancer: a clinical guide to therapy. Edited by H. Bleiberg, N. Kemeny, P. Rougier and H. Wilke. Martin Dunitz Ltd., London, 2002; pp39-45.
Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Intl J Radiat Oncol 2002;53:1111-1116.
Zhou HB, Weaver MA, Qin J, Longnecker MP, Wang MC. A semiparametric empirical likelihood method for data from an outcome-dependent sampling scheme with a continuous outcome. Biometrics 2002;58:413-421
